Department of Haematology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.
Division of Hematology and Medical Oncology, Oregon Health and Science University/Knight Cancer Institute, Portland, OR, USA.
Support Care Cancer. 2022 Oct;30(10):8511-8517. doi: 10.1007/s00520-022-07138-8. Epub 2022 May 17.
Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.
血栓形成是癌症患者死亡的第二大主要原因。患有胰腺癌（PC）的患者发生静脉血栓栓塞症（VTE）的风险非常高。尽管初级门诊血栓预防（PATP）可以降低这种风险，但在抗凝剂的选择和剂量、抗凝治疗持续时间以及患者选择标准方面仍存在不确定因素。此外，目前关于 PC 患者 PATP 的实践指南也存在分歧。本综述批判性地评估了化疗中接受 PATP 的 PC 患者使用 PATP 的证据。
